4-PHENYLPIPERIDINE COMPOUNDS
    2.
    发明授权
    4-PHENYLPIPERIDINE COMPOUNDS 失效
    4-苯基哌啶类化合物

    公开(公告)号:EP0994872B1

    公开(公告)日:2001-04-25

    申请号:EP97926276.3

    申请日:1997-06-10

    申请人: Synthon B.V.

    IPC分类号: C07D405/12 A61K31/445

    CPC分类号: C07D405/12 C07D211/20

    摘要: The invention relates to a compound, and pharmaceutically acceptable salts, having formula (I), wherein: R represents an alkyl or alkynyl group having 1-4 carbon atoms, or a phenyl group optionally substituted by C1-4 alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl or methylenedioxy, or represents tetrahydronaphthyl; R1 represents hydrogen, trifluoro (C¿1-4?) alkyl, alkyl or alkynyl; X represents hydrogen, alkyl having 1-4 carbon atoms, alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio or aralkoxy; R?2¿ represents: a C¿1?-C10 alkyl group; a phenyl group optionally substituted by one or more of the following groups: a C1-C10 alkyl group, a halogen group, a nitro group, hydroxy group, and/or an alkoxy group.

    摘要翻译: 本发明涉及具有式(I)的化合物及其药学上可接受的盐,其中:R表示具有1-4个碳原子的烷基或炔基或任选被C 1-4烷基,烷硫基,烷氧基, 卤素,硝基,酰基氨基,甲基磺酰基或亚甲基二氧基,或代表四氢萘基; R1代表氢,三氟(C1-4)烷基,烷基或炔基; X代表氢,具有1-4个碳原子的烷基,烷氧基,三氟烷基,羟基,卤素,甲硫基或芳烷氧基; R 2'代表:C 1 -C 10烷基; 任选被一个或多个以下基团取代的苯基:C1-C10烷基,卤素基团,硝基,羟基和/或烷氧基。

    4-PHENYLPIPERIDINE COMPOUNDS
    7.
    发明授权
    4-PHENYLPIPERIDINE COMPOUNDS 失效
    4-苯基哌啶化合物

    公开(公告)号:EP0994872B9

    公开(公告)日:2001-12-05

    申请号:EP97926276.3

    申请日:1997-06-10

    申请人: Synthon B.V.

    IPC分类号: C07D405/12 A61K31/445

    CPC分类号: C07D405/12 C07D211/20

    摘要: The invention relates to a compound, and pharmaceutically acceptable salts, having formula (I), wherein: R represents an alkyl or alkynyl group having 1-4 carbon atoms, or a phenyl group optionally substituted by C1-4 alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl or methylenedioxy, or represents tetrahydronaphthyl; R1 represents hydrogen, trifluoro (C¿1-4?) alkyl, alkyl or alkynyl; X represents hydrogen, alkyl having 1-4 carbon atoms, alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio or aralkoxy; R?2¿ represents: a C¿1?-C10 alkyl group; a phenyl group optionally substituted by one or more of the following groups: a C1-C10 alkyl group, a halogen group, a nitro group, hydroxy group, and/or an alkoxy group.

    4-PHENYLPIPERIDINE COMPOUNDS
    8.
    发明公开
    4-PHENYLPIPERIDINE COMPOUNDS 失效
    4-苯基衍生物

    公开(公告)号:EP0994872A1

    公开(公告)日:2000-04-26

    申请号:EP97926276.3

    申请日:1997-06-10

    申请人: Synthon B.V.

    IPC分类号: C07D405/12 A61K31/445

    CPC分类号: C07D405/12 C07D211/20

    摘要: The invention relates to a compound, and pharmaceutically acceptable salts, having formula (I), wherein: R represents an alkyl or alkynyl group having 1-4 carbon atoms, or a phenyl group optionally substituted by C1-4 alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl or methylenedioxy, or represents tetrahydronaphthyl; R1 represents hydrogen, trifluoro (C¿1-4?) alkyl, alkyl or alkynyl; X represents hydrogen, alkyl having 1-4 carbon atoms, alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio or aralkoxy; R?2¿ represents: a C¿1?-C10 alkyl group; a phenyl group optionally substituted by one or more of the following groups: a C1-C10 alkyl group, a halogen group, a nitro group, hydroxy group, and/or an alkoxy group.

    MODIFIED RELEASE TAMSULOSIN TABLETS

    公开(公告)号:EP1441713B2

    公开(公告)日:2018-11-14

    申请号:EP02780143.0

    申请日:2002-11-06

    申请人: Synthon B.V.

    摘要: The invention relates to a pharmaceutical tablet comprising a tablet matrix having dispersed therein 0.1 to 10 mg of tamsulosin or a pharmaceutically acceptable salt thereof, and optionally having an enteric coating over said matrix, wherein said tablet is a modified release tablet and has a dissolution profile such that in each of the media SIF, FaSSIF, and FeSSIF, said tablet releases not more than 60% of said tamsulosin at 2 hours elapsed time in USP 2 apparatus using 500 ml of said media at 50-100 rpm paddle speed, to a monolithic pharmaceutical tablet, comprising 0.1 to 10 mg of tamsulosin or a pharmaceutically acceptable salt thereof, 10 wt% - 90 wt% hydroxypropyl methylcellulose, and a total tablet weight of 10 to 300 mg, to a unit dosage form for treating or ameliorating the conditions of benign prostatic hyperplasia comprising an effective amount of one or more tablets as mentioned above, and to a method for treating the symptoms of benign prostatic hyperplasia, which comprises administering to a patient in need thereof one or more tablets as mentioned above.